@WTO Public Forum 2017/ SDG3: Trading globally for better health
Date
28 September 2017
Time
08:30 to 10:00
Location
WTO Rue de Lausanne
Attendance
This event has now passed. To browse our upcoming events click here.
The Sustainable Development Goals (SDGs) take a holistic and multifaceted approach, interweaving health considerations into all of the goals. Sitting at the core of Goal #3 on health is the powerful concept of Universal Health Coverage (UHC). If you are registered at WTO Public Forum 2017, come and join us Thursday 28 September here to hear private sector perspective on SDG3: trading for better health! IFPMA Assistant Director General Fumie Griego will be speaking on our behalf.
Program
The Sustainable Development Goals (SDGs) take a holistic and multifaceted approach, interweaving health considerations into all of the goals. Sitting at the core of Goal #3 on health is the powerful concept of Universal Health Coverage (UHC). WTO rules are relevant to nearly every aspect on the long road from labs to patients. R&D services on a given pharmaceutical product are performed globally; active intermediate ingredients are procured in different from multiple (developing and developed) countries; finished products are traded globally and subject to stringent regulatory procedures. The modern multilateral framework of international trade has allowed the emergence of a successful innovative ecosystem in the pharma sector that has consistently delivered innovations to patients worldwide. Recent calls for renewed protectionist measures, risks jeopardizing industry’s capacity to innovate and trade globally, with serious consequences on global health and the achievements of the SDGs. This panel will discuss how modern multilateral framework of international trade has contributed to an innovative ecosystem in the pharma sector and how it can further contribute to achieving the SDGs.
Speakers
Fumie Griego was appointed IFPMA’s Assistant Director General for Strategic Planning, Policy and Research on 1 May 2017. Fumie leads IFPMA’s work on health economics and policy such as value of medicines, pricing and reimbursement, and metrics/evaluation. Prior to joining IFPMA, Fumie was Head of Global Oncology Policy and Strategy, Global Government Affairs & Policy at Merck KGaA and Vice President for International Health Policy at Pharmaceutical Research and Manufacturers of America (PhRMA). Prior to joining PhRMA, Fumie was as a senior economist in the White House’s Office of Management and Budget where she provided U.S. senior officials in both the Bush and Obama Administrations with policy advice on a range of health policy issues. Fumie holds a PhD in Health Policy from Harvard University and a Bachelor and Master of Science degrees in Earth Systems (concentration in environmental economics and policy) from Stanford University
Matthias Bauer is Senior Economist at ECIPE. His areas of research include international trade, the economics of digital markets and the digital economy, European Single Market integration, European fiscal affairs and capital market policy.
Matthias studied business administration at the University of Hull, UK, and economics at the Friedrich Schiller University Jena, Germany. He received his Ph.D. degree after joining the Bundesbank graduate programme on the ‘Foundations of Global Financial Markets and Financial Stability’. Before joining ECIPE, Matthias was the Coordinator of International Political Economy at the international cooperation division of Konrad Adenauer Foundation, Berlin. Previously, Matthias held positions at DekaBank, UBS, Mercedes-Benz China, and worked as a start-up and business development consultant.
Jennifer Brant is the Director of Innovations Insights, a cross-industry group contributing business perspectives on policies that best support the development of solutions to societies’ greatest challenges. Based in Geneva, Jennifer previously worked at Sidley Austin LLP and Oxfam International on international trade policy issues. She has graduate degrees in international law, economics, and development studies from the Graduate Institute of International Studies in Geneva and Johns Hopkins SAIS.